Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial
- PMID: 18054932
- DOI: 10.1016/j.fertnstert.2007.06.029
Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial
Abstract
Objective: To evaluate the effectiveness of a GnRH antagonist in preventing premature LH surge under a letrozole and gonadotropin protocol.
Design: Prospective, randomized clinical trial.
Setting: A teaching hospital and tertiary medical center.
Patient(s): Sixty-one patients were randomly assigned into two letrozole and gonadotropin-treated groups. These were distinguished by the absence (group I) or presence (group II) of supplementation with 0.25 mg of cetrorelix.
Intervention(s): Controlled ovarian stimulation with letrozole and gonadotropins, cetrorelix and intrauterine insemination.
Main outcome measure(s): Rate of premature LH surge.
Result(s): Compared with group I, the rate of premature LH surge was statistically significantly lower for group II (43.4% [13/30] vs. 19.4% [6/31]), but the amount of gonadotropins used was statistically significantly higher (817.5 +/- 28.5 vs. 907.5 +/- 27.3 IU). Patients with premature LH surge had a statistically significantly lower pregnancy rate (21.4% [9/42] vs. 0 [0/18]) relative to their unaffected counterparts.
Conclusion(s): A flexible protocol of 0.25 mg of cetrorelix for IUI cycles appears to suppress the rate of premature LH surge during ovarian stimulation with letrozole and gonadotropins. However, the incidence of premature LH surge remains too high, and modification will be necessary before the application of cetrorelix to IVF treatment.
Similar articles
-
GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1323-36. doi: 10.1517/17425250903279969. Expert Opin Drug Metab Toxicol. 2009. PMID: 19761413 Review.
-
Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.Fertil Steril. 2008 Mar;89(3):620-4. doi: 10.1016/j.fertnstert.2007.03.035. Epub 2007 Aug 6. Fertil Steril. 2008. PMID: 17678911 Clinical Trial.
-
GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial.Hum Reprod. 2007 Jan;22(1):101-8. doi: 10.1093/humrep/del337. Epub 2006 Oct 10. Hum Reprod. 2007. PMID: 17032732 Clinical Trial.
-
GnRH antagonists in ovarian stimulation for IVF.Hum Reprod Update. 2006 Jul-Aug;12(4):333-40. doi: 10.1093/humupd/dml001. Epub 2006 Mar 27. Hum Reprod Update. 2006. PMID: 16567347 Review.
-
Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.Hum Reprod. 2005 May;20(5):1200-6. doi: 10.1093/humrep/deh741. Epub 2005 Jan 21. Hum Reprod. 2005. PMID: 15665010 Clinical Trial.
Cited by
-
The cumulative live birth rate and cost-effectiveness of the clomiphene and gonadotropin cotreatment protocol versus the mid-luteal GnRH agonist protocol in women over 35 years old.Sci Rep. 2024 Jun 5;14(1):12894. doi: 10.1038/s41598-024-63842-x. Sci Rep. 2024. PMID: 38839827 Free PMC article.
-
Chronic Estrus Disrupts Uterine Gland Development and Homeostasis.Endocrinology. 2022 Mar 1;163(3):bqac011. doi: 10.1210/endocr/bqac011. Endocrinology. 2022. PMID: 35134138 Free PMC article.
-
A Premature Rise of Luteinizing Hormone Is Associated With a Reduced Cumulative Live Birth Rate in Patients ≥37 Years Old Undergoing GnRH Antagonist In Vitro Fertilization Cycles.Front Endocrinol (Lausanne). 2021 Dec 2;12:722655. doi: 10.3389/fendo.2021.722655. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34925227 Free PMC article.
-
Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.Sci Rep. 2021 Nov 23;11(1):22732. doi: 10.1038/s41598-021-02227-w. Sci Rep. 2021. PMID: 34815477 Free PMC article.
-
Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility.Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD005356. doi: 10.1002/14651858.CD005356.pub3. Cochrane Database Syst Rev. 2021. PMID: 34739136 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
